A Comparison of SYMBICORT® pMDI With Formoterol Turbuhaler® in Subjects With COPD
Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if SYMBICORT® delivered via a pressurized
metered-dose inhaler, referred to as a pMDI, is effective in preventing COPD exacerbations.
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Treatments:
Budesonide Budesonide, Formoterol Fumarate Drug Combination Formoterol Fumarate